US4133814A
(en)
|
1975-10-28 |
1979-01-09 |
Eli Lilly And Company |
2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
|
US4418068A
(en)
|
1981-04-03 |
1983-11-29 |
Eli Lilly And Company |
Antiestrogenic and antiandrugenic benzothiophenes
|
GB8327256D0
(en)
|
1983-10-12 |
1983-11-16 |
Ici Plc |
Steroid derivatives
|
DE4126999A1
(de)
|
1991-08-16 |
1993-02-18 |
Basf Ag |
Herbizide mittel, enthaltend 3-aminobenzo(b)thiophene als antidots
|
CA2083891A1
(en)
|
1991-12-03 |
1993-06-04 |
Angus Murray Macleod |
Heterocyclic compounds, compositions containing them and their use in therapy
|
CZ285937B6
(cs)
|
1992-01-16 |
1999-12-15 |
Hoechst Aktiengesellschaft |
Arylcykloalkylové deriváty, způsob přípravy těchto derivátů a jejich použití
|
TW366342B
(en)
|
1992-07-28 |
1999-08-11 |
Lilly Co Eli |
The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
|
EP0622673B1
(en)
|
1993-04-24 |
1998-02-04 |
Kodak Limited |
Photographic colour couplers and photographic materials containing them
|
US5478847A
(en)
|
1994-03-02 |
1995-12-26 |
Eli Lilly And Company |
Methods of use for inhibiting bone loss and lowering serum cholesterol
|
US5834468A
(en)
|
1995-07-07 |
1998-11-10 |
Zeneca Limited |
Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
|
US6458811B1
(en)
|
1996-03-26 |
2002-10-01 |
Eli Lilly And Company |
Benzothiophenes formulations containing same and methods
|
US5780497A
(en)
|
1996-04-19 |
1998-07-14 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
US5880137A
(en)
|
1996-04-19 |
1999-03-09 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
US5998402A
(en)
|
1996-04-19 |
1999-12-07 |
American Home Products Corporation |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
|
TW397821B
(en)
|
1996-04-19 |
2000-07-11 |
American Home Produits Corp |
3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
|
WO1998033798A2
(en)
|
1997-02-05 |
1998-08-06 |
Warner Lambert Company |
Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
CA2306489A1
(en)
|
1997-10-03 |
1999-04-15 |
Mark Gregory Stocksdale |
Benzothiophenes
|
US6005102A
(en)
|
1997-10-15 |
1999-12-21 |
American Home Products Corporation |
Aryloxy-alkyl-dialkylamines
|
UA68365C2
(en)
|
1997-11-06 |
2004-08-16 |
Wyeth Corp |
Peroral contraception by combination of anti-estrogen and progestin
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
US6479535B1
(en)
|
1998-05-15 |
2002-11-12 |
Wyeth |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
|
US6583170B1
(en)
|
1998-05-15 |
2003-06-24 |
Wyeth |
2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
CO5251465A1
(es)
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
US7091240B2
(en)
|
2000-03-10 |
2006-08-15 |
Oxigene, Inc. |
Tubulin binding ligands and corresponding prodrug constructs
|
US20020013327A1
(en)
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
UA74370C2
(uk)
|
2000-06-26 |
2005-12-15 |
Пфайзер Продактс Інк. |
Піроло(2,3-d)піримідинові сполуки як імуносупресори
|
AU2001273144A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Use of substituted indole compounds for treating neuropeptide y-related conditions
|
MXPA02012896A
(es)
|
2000-07-06 |
2003-10-24 |
Wyeth Corp |
Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos.
|
AU2001271784A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Therapy for prosthesis-related bone degeneration
|
AU2001271782A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Use of substituted insole compounds for treating excessive intraocular pressure
|
AU2001271781A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Use of substituted indole compounds for treating sphincter incontinence
|
US20020016318A1
(en)
|
2000-07-06 |
2002-02-07 |
American Home Products Corporation |
Methods of treating breast disorders
|
WO2002003975A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Combinations of ssri and estrogenic agents
|
AR030064A1
(es)
|
2000-07-06 |
2003-08-13 |
Wyeth Corp |
Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
|
JP2004502730A
(ja)
|
2000-07-06 |
2004-01-29 |
ワイス |
ビスホスホネート、エストロゲン剤および所望によるエストロゲンの組み合わせ
|
EP1296674A2
(en)
|
2000-07-06 |
2003-04-02 |
Wyeth |
Use of substituted indole compounds for increasing nitric oxide synthase activity
|
EP1177787A3
(en)
|
2000-07-28 |
2003-09-10 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating cataracts
|
PT1318837E
(pt)
|
2000-08-11 |
2004-12-31 |
Wyeth Corp |
Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
|
EP1192945A3
(en)
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
IL145838A
(en)
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
PL220952B1
(pl)
|
2002-01-22 |
2016-01-29 |
Warner Lambert Co |
2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
|
AU2003281632A1
(en)
|
2002-07-24 |
2004-02-09 |
Eli Lilly And Company |
Dihydro-dibenzo(b,e)oxepine based selective estrogen receptor modulators, compositions and methods
|
EP1590341B1
(en)
|
2003-01-17 |
2009-06-17 |
Warner-Lambert Company LLC |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
DK1648889T3
(da)
|
2003-07-11 |
2009-01-05 |
Warner Lambert Co |
Isethionatsalt af en selektiv CDK4-inhibitor
|
WO2005016929A1
(en)
|
2003-08-15 |
2005-02-24 |
Astrazeneca Ab |
Fused heterocylcles as inhibitors of glutamate racemase (muri)
|
KR100798161B1
(ko)
|
2003-10-23 |
2008-01-28 |
에프. 호프만-라 로슈 아게 |
신경병적 또는 신경정신병적 장애의 치료에서 glyt-1저해제로서 사용하기 위한 트라이아자-스피로피페리딘유도체
|
JP2005129430A
(ja)
|
2003-10-27 |
2005-05-19 |
Konica Minolta Holdings Inc |
光電変換材料用半導体、光電変換素子及び太陽電池
|
FR2862646B1
(fr)
|
2003-11-20 |
2006-02-24 |
Merck Sante Sas |
Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
|
GB0327380D0
(en)
|
2003-11-25 |
2003-12-31 |
Cyclacel Ltd |
Method
|
WO2005058842A1
(en)
|
2003-12-15 |
2005-06-30 |
Laboratoire Theramex |
1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them
|
ITMI20040874A1
(it)
|
2004-04-30 |
2004-07-30 |
Ist Naz Stud Cura Dei Tumori |
Derivati indolici ed azaindolici con azione antitumorale
|
AU2006205851A1
(en)
|
2005-01-14 |
2006-07-20 |
Janssen Pharmaceutica N.V. |
5-membered annelated heterocyclic pyrimidines as kinase inhibitors
|
US7399767B2
(en)
|
2005-01-21 |
2008-07-15 |
Ortho-Mcneil Pharmaceutical, Inc. |
Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
|
CA2597447C
(en)
|
2005-02-14 |
2014-03-25 |
Bionomics Limited |
Novel tubulin polymerisation inhibitors
|
EP1779848A1
(en)
|
2005-10-28 |
2007-05-02 |
Nikem Research S.R.L. |
V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
|
ES2386299T3
(es)
|
2006-02-03 |
2012-08-16 |
Bionomics Limited |
Benzofuranos, benzotiofenos, benzoselenofenos e indoles sustituidos y su uso como inhibidores de la polimerización de tubulina
|
ES2436028T3
(es)
|
2006-06-23 |
2013-12-26 |
Radius Health, Inc. |
Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno
|
EP1947085A1
(en)
|
2007-01-19 |
2008-07-23 |
Laboratorios del Dr. Esteve S.A. |
Substituted indole sulfonamide compounds, their preparation and use as medicaments
|
US20110002855A1
(en)
|
2007-06-25 |
2011-01-06 |
Neurogen Corporation |
Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
|
KR20100027231A
(ko)
|
2007-07-25 |
2010-03-10 |
에프. 호프만-라 로슈 아게 |
벤조퓨란- 및 벤조[b]티오펜-2-카복실산 아마이드 유도체 및 이의 히스타민 3 수용체 조절제로서의 용도
|
WO2009061345A2
(en)
|
2007-11-07 |
2009-05-14 |
Cornell Research Foundation, Inc. |
Targeting cdk4 and cdk6 in cancer therapy
|
JP5537439B2
(ja)
|
2007-12-19 |
2014-07-02 |
アムジエン・インコーポレーテツド |
細胞周期阻害剤としての縮合ピリジン、ピリミジンおよびトリアジン化合物
|
EP2320903B1
(en)
|
2008-07-29 |
2017-01-18 |
Nerviano Medical Sciences S.r.l. |
THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
|
US8685980B2
(en)
|
2008-08-22 |
2014-04-01 |
Novartis Ag |
Pyrrolopyrimidine compounds and their uses
|
EP2341906A4
(en)
|
2008-10-01 |
2012-06-13 |
Univ North Carolina |
HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE INHIBITORS OF CYCLINE DEPENDENT KINASES 4/6
|
CN102231984A
(zh)
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
|
WO2010075542A1
(en)
|
2008-12-23 |
2010-07-01 |
Curis, Inc. |
Cdk inhibitors
|
WO2010093578A1
(en)
|
2009-02-10 |
2010-08-19 |
Glaxo Group Limited |
Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
|
WO2010127452A1
(en)
|
2009-05-04 |
2010-11-11 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
5-oxo-ete receptor antagonist compounds
|
CA2761896A1
(en)
|
2009-05-13 |
2010-11-18 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
US9040519B2
(en)
|
2010-02-18 |
2015-05-26 |
Medivation Technologies, Inc. |
Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
WO2011136828A1
(en)
|
2010-04-27 |
2011-11-03 |
The Johns Hopkins University |
Immunogenic compositions and methods for treating neoplasia
|
MX2012014431A
(es)
|
2010-06-10 |
2013-02-26 |
Aragon Pharmaceuticals Inc |
Modulares del receptor de estrogenos y usos de los mismos.
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
US8642632B2
(en)
|
2010-07-02 |
2014-02-04 |
Radius Health, Inc. |
Selective androgen receptor modulators
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
US10005750B2
(en)
|
2010-10-06 |
2018-06-26 |
J-Pharma Co., Ltd. |
Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
RU2621674C2
(ru)
|
2010-10-25 |
2017-06-07 |
Г1 Терапьютикс Инк., |
Ингибиторы cdk
|
JP5886873B2
(ja)
|
2010-12-24 |
2016-03-16 |
メルク・シャープ・エンド・ドーム・ベー・フェー |
N置換アゼチジン誘導体
|
DE102011087987A1
(de)
|
2011-12-08 |
2013-06-13 |
Bayer Intellectual Property Gmbh |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
WO2013090829A1
(en)
|
2011-12-14 |
2013-06-20 |
Aragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
MD20140054A2
(ro)
|
2011-12-16 |
2014-10-31 |
Olema Pharmaceuticals, Inc. |
Compuşi noi de benzopiran, compoziţii şi utilizări ale acestora
|
BR112014017985A8
(pt)
|
2012-01-31 |
2017-07-11 |
Novartis Ag |
Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
|
PE20142461A1
(es)
|
2012-03-20 |
2015-02-05 |
Seragon Pharmaceuticals Inc |
Moduladores del receptor de estrogeno y sus usos
|
CA2868966C
(en)
|
2012-03-29 |
2021-01-26 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
CA2870019C
(en)
|
2012-04-26 |
2020-08-18 |
Francis Xavier Tavares |
Synthesis of lactams
|
BR112015004539A2
(pt)
|
2012-09-05 |
2017-07-04 |
Koninklijke Philips Nv |
cápsula de preparação de bebida; dispositivo de produção de bebida; sistema de produção de bebida a partir de uma cápsula; e método de preparação de bebida que utiliza uma cápsula de porção única
|
CA2928173C
(en)
*
|
2012-10-24 |
2021-10-19 |
The Board Of Trustees Of The University Of Illinois |
Compositions comprising benzothiophene derivatives and use thereof for treatment of estrogen-related medical disorders
|
US20150284357A1
(en)
|
2012-10-24 |
2015-10-08 |
Gregory R. Thatcher |
Compositions and methods for treating estrogen-related medical disorders
|
MY174888A
(en)
*
|
2013-02-19 |
2020-05-20 |
Novartis Ag |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
|
US9586952B2
(en)
|
2013-03-14 |
2017-03-07 |
Genentech, Inc. |
Polycyclic estrogen receptor modulators and uses thereof
|
US9527857B2
(en)
|
2013-03-15 |
2016-12-27 |
GI Therapeutics, Inc. |
HSPC-sparing treatments for RB-positive abnormal cellular proliferation
|
US20140274896A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
CN105407723A
(zh)
|
2013-03-15 |
2016-03-16 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
PL3004090T3
(pl)
|
2013-05-28 |
2018-02-28 |
Astrazeneca Ab |
Związki chemiczne
|
JP6389517B2
(ja)
|
2013-06-19 |
2018-09-12 |
セラゴン ファーマシューティカルズ, インク. |
アゼチジンエストロゲン受容体調節因子及びその使用
|
KR20160021277A
(ko)
|
2013-06-19 |
2016-02-24 |
세라곤 파마슈티컬스, 인크. |
에스트로겐 수용체 조절제 및 이의 용도
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
WO2015028409A1
(de)
|
2013-08-27 |
2015-03-05 |
Bayer Pharma Aktiengesellschaft |
6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
US20160257688A1
(en)
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
US20150258080A1
(en)
|
2014-03-13 |
2015-09-17 |
Genentech, Inc. |
Therapeutic combinations with estrogen receptor modulators
|
BR112016020953A2
(pt)
|
2014-03-13 |
2018-01-23 |
Hoffmann La Roche |
composto, kit, composição farmacêutica, uso de composto, método de tratamento e invenção
|
PL3122426T3
(pl)
|
2014-03-28 |
2023-05-15 |
Duke University |
Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego
|
WO2015161287A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of normal cells during chemotherapy
|
US20160020862A1
(en)
*
|
2014-07-17 |
2016-01-21 |
Qualcomm Incorporated |
Impedance tuning for a power amplifier load tuner, a receive tuner, and an antenna tuner
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
CN107406433A
(zh)
|
2014-12-18 |
2017-11-28 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的2,3‑二苯基色烯的衍生物
|
WO2016097072A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
EP3233828B1
(en)
|
2014-12-18 |
2020-03-04 |
F. Hoffmann-La Roche AG |
Estrogen receptor modulators and uses thereof
|
WO2016174551A1
(en)
|
2015-04-27 |
2016-11-03 |
Pfizer Inc. |
Anti-estrogenic compounds
|
CN107531722B
(zh)
|
2015-05-26 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
杂环雌激素受体调节剂及其用途
|
EP3312184A4
(en)
|
2015-06-16 |
2019-02-27 |
Jiangsu Hengrui Medicine Co., Ltd. |
PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
|
AU2016331065B2
(en)
|
2015-10-01 |
2021-04-29 |
Olema Pharmaceuticals, Inc. |
Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs
|
WO2017056115A1
(en)
|
2015-10-03 |
2017-04-06 |
Sun Pharma Advanced Research Company Limited |
Novel n-aryl containing fused heterocyclic compounds
|
CN108137511A
(zh)
|
2015-10-07 |
2018-06-08 |
豪夫迈·罗氏有限公司 |
制备(e)-3-(4-((e)-2-(2-氯-4-氟苯基)-1-(1h-吲唑-5-基)丁-1-烯-1-基)苯基)丙烯酸的方法
|
EP3368519B1
(en)
|
2015-10-27 |
2022-04-06 |
Sun Pharma Advanced Research Company Limited |
Novel heterocyclic antiestrogens
|
US10399939B2
(en)
|
2015-11-09 |
2019-09-03 |
Genentech, Inc. |
Tetrahydronaphthalene estrogen receptor modulators and uses thereof
|
KR102099159B1
(ko)
|
2015-11-12 |
2020-04-10 |
쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 |
아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법
|
EP3386968A4
(en)
|
2015-12-09 |
2019-09-25 |
The Board of Trustees of the University of Illinois |
BENZOTHIOPHEN-BASED SELECTIVE ESTROGEN RECEPTOR-DOWN-REGULATING PREPARATIONS
|
KR102445288B1
(ko)
|
2016-07-01 |
2022-09-19 |
쥐원 쎄라퓨틱스, 인크. |
N-(헤테로아릴)-피롤로[3,2-d]피리미딘-2-아민의 합성
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
EA201990187A1
(ru)
|
2016-07-01 |
2019-07-31 |
Г1 Терапьютикс, Инк. |
Антипролиферационные средства на основе пиримидина
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
IL303038B1
(en)
|
2016-12-05 |
2024-04-01 |
G1 Therapeutics Inc |
Preservation of immune response during chemotherapy regimens
|
US11395821B2
(en)
|
2017-01-30 |
2022-07-26 |
G1 Therapeutics, Inc. |
Treatment of EGFR-driven cancer with fewer side effects
|
AU2018217809A1
(en)
|
2017-02-10 |
2019-08-22 |
G1 Therapeutics, Inc. |
Benzothiophene estrogen receptor modulators
|
AU2018291026B2
(en)
|
2017-06-29 |
2022-09-01 |
G1 Therapeutics, Inc. |
Morphic forms of GIT38 and methods of manufacture thereof
|
CN111867592A
(zh)
|
2018-01-04 |
2020-10-30 |
G1治疗公司 |
用于治疗异常细胞增殖的杂环化合物
|
EP3738084A4
(en)
|
2018-01-08 |
2021-11-17 |
G1 Therapeutics, Inc. |
G1T38 SUPERIOR DOSAGE RATES
|
CN112218634A
(zh)
|
2018-04-09 |
2021-01-12 |
G1治疗公司 |
具有驱动致癌突变的癌症的治疗
|
AU2019321677A1
(en)
|
2018-08-16 |
2021-03-11 |
G1 Therapeutics, Inc. |
Benzothiophene estrogen receptor modulators to treat medical disorders
|
KR20210049847A
(ko)
|
2018-08-24 |
2021-05-06 |
쥐원 쎄라퓨틱스, 인크. |
1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
|
EP3877422A4
(en)
|
2018-11-09 |
2022-08-24 |
G1 Therapeutics, Inc. |
THERAPEUTIC DOSING SCHEDULES FOR THE TREATMENT OF CANCER WITH ERIBULIN AND SELECTIVE CDK4/6 INHIBITOR COMBINATIONS
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|